Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
CMPX 
Compass Therapeutics Inc. (CMPX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/16/2025: CMPX (5-star) is a STRONG-BUY. BUY since 4 days. Simulated Profits (2.27%). Updated daily EoD!
Upturn Star Rating
Outstanding Performance
These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.
Number of Analysts
9 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $13.2
1 Year Target Price $13.2
| 7 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 199.42% | Avg. Invested days 31 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  5.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 09/16/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 633.10M USD | Price to earnings Ratio - | 1Y Target Price 13.2 |
Price to earnings Ratio - | 1Y Target Price 13.2 | ||
Volume (30-day avg) 9 | Beta 1.31 | 52 Weeks Range 1.27 - 4.08 | Updated Date 09/16/2025 |
52 Weeks Range 1.27 - 4.08 | Updated Date 09/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.45 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -31.14% | Return on Equity (TTM) -51.84% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 521468817 | Price to Sales(TTM) 439.25 |
Enterprise Value 521468817 | Price to Sales(TTM) 439.25 | ||
Enterprise Value to Revenue 109.28 | Enterprise Value to EBITDA -8.92 | Shares Outstanding 171572000 | Shares Floating 100795496 |
Shares Outstanding 171572000 | Shares Floating 100795496 | ||
Percent Insiders 11.42 | Percent Institutions 62.64 |
Upturn AI SWOT
Compass Therapeutics Inc.
Company Overview
History and Background
Compass Therapeutics, Inc. was founded in 2014. It is a clinical-stage biopharmaceutical company focused on developing proprietary antibody therapeutics to treat various human diseases.
Core Business Areas
- Antibody Therapeutics Development: Focused on developing novel antibody therapeutics targeting cancer and other diseases.
- Bispecific and Multispecific Antibodies: Creating antibody-based therapeutics with multiple binding specificities for enhanced efficacy.
- Drug Discovery and Research: Employing its proprietary Stellabody and other platforms to discover and develop new therapeutic candidates.
Leadership and Structure
Thomas J. Schuetzle, MD is the current CEO. The company has a board of directors and a management team overseeing research, development, and operations.
Top Products and Market Share
Key Offerings
- CTX-471: A fully human agonistic antibody targeting CD137 (4-1BB). It is currently in clinical trials for solid tumors. No market share data yet as it is in development. Competitors include Bristol Myers Squibb (Opdivo + relatlimab combination) and other immuno-oncology companies developing similar therapies.
- CTX-857: A fully human monoclonal antibody targeting PD-1 currently in clinical trials. No market share data yet as it is in development. Competitors include Merck (Keytruda) and Bristol Myers Squibb (Opdivo).
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive, with numerous companies developing new therapies for a wide range of diseases, especially in oncology and immunology.
Positioning
Compass Therapeutics is positioned as a clinical-stage company focused on innovative antibody therapeutics, seeking to differentiate through its proprietary technology platforms and unique targets.
Total Addressable Market (TAM)
The oncology and immunology TAM is estimated to be hundreds of billions of dollars. Compass is positioned to capture a share of this market through its novel antibody therapeutics, targeting specific unmet needs in cancer treatment.
Upturn SWOT Analysis
Strengths
- Proprietary technology platforms (Stellabody)
- Novel antibody therapeutics pipeline
- Experienced management team
- Focus on immuno-oncology
Weaknesses
- Clinical-stage company with no approved products
- High cash burn rate
- Dependence on clinical trial success
- Relatively small size compared to major pharmaceutical companies
Opportunities
- Positive clinical trial results
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline through new targets and indications
- Acquisition by a larger company
Threats
- Clinical trial failures
- Competition from established immuno-oncology therapies
- Regulatory hurdles
- Financing challenges
Competitors and Market Share
Key Competitors
- MRK
- BMY
- LLY
Competitive Landscape
Compass Therapeutics competes with large pharmaceutical companies with established immuno-oncology therapies. Its advantages lie in its novel targets and technology platforms, while its disadvantages are its smaller size and limited resources.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by pipeline advancement and collaborations, but limited by the lack of approved products.
Future Projections: Future growth is highly dependent on positive clinical trial results and potential partnerships. Analyst estimates vary widely, reflecting the inherent uncertainty of drug development.
Recent Initiatives: Recent initiatives include advancing clinical trials for CTX-471 and CTX-857, and exploring new targets and indications for its Stellabody platform.
Summary
Compass Therapeutics is a clinical-stage biopharmaceutical company with a promising pipeline of antibody therapeutics. The company's strengths include its proprietary technology platforms and focus on immuno-oncology. However, it faces challenges related to clinical trial success, competition, and financing. Positive clinical trial results and strategic partnerships will be crucial for future growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q)
- Company Website
- Analyst Reports
- ClinicalTrials.gov
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Investing in biotechnology companies is inherently risky, and investors should conduct their own due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Compass Therapeutics Inc.
Exchange NASDAQ | Headquaters Boston, MA, United States | ||
IPO Launch date 2021-04-05 | CEO & Vice Chairman Dr. Thomas J. Schuetz M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 35 | |
Full time employees 35 | |||
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in the development of antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidates include tovecimig, a bispecific antibody that blocks Delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A) signaling pathways, which are critical to angiogenesis and tumor vascularization; CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells; and CTX-8371, a bispecific inhibitor that targets programmed cell death protein-1 (PD-1) and ligand PD-L1 checkpoint inhibitor antibodies. It also develops CTX-10726, a bispecific antibody that targets PD-1 and VEFG-A; and VEGF-IO Bispecific / Multiple, a bispecific antibody engages the angiogenesis pathway and anti-tumor immune that targets, including immune checkpoints, as well as analyzes VEGF combinations with other immune response-related proteins. Compass Therapeutics, Inc. was founded in 2014 and is headquartered in Boston, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.